Alumis Inc. Common Stock (ALMS) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash ⢠Deep Losses ⢠Rich Valuation ALMS has a strong liquidity cushion and moderate leverage, but its severe losses, negative cash flow, and rich valuation relative to weak fundamentals make it a high-risk, turnaround-dependent investment.
Price Behavior
Key Price Behavior Insights: ⢠Rebound holding ⢠Resistance overhead ⢠Support critical Support Level: $24.16-$24.71, especially $23.37 Resistance Level: $27.00-$29.00 ALMS has rebounded strongly over the last month from the low $20s into the mid-$20s, but the move is still choppy and needs to hold above $24/$23.37 to keep resistance near $27â$29 in play.
Sentiment & News
Key News Insights: ⢠Phase 3 strength ⢠NDA pathway ⢠Pipeline optionality Alumis' envudeucitinib continues to show strong Phase 3 psoriasis momentum, supporting potential 2026 NDA filing and a more competitive profile versus larger rivals.
AI Summary
ALMS should now be viewed less as a cash-burning biotech option and more as a late-stage psoriasis story with real upside from envudeucitinib's Phase 3 strength, but the trade is still highly binary because approval, commercial differentiation, and execution must arrive before heavy cash burn, dilution risk, and TYK2 competition compress the thesis.
Description
Alumis Inc. is a clinical-stage biopharmaceutical company developing allosteric TYK2 inhibitors to treat autoimmune conditions. Its lead program, ESK-001, is in clinical development for dermatologic, systemic and ocular autoimmune disorders, while A-005 is a CNS-penetrant candidate intended for neuroinflammatory and neurodegenerative indications. The company was incorporated in 2021, renamed from Esker Therapeutics in January 2022, and is based in South San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 29 | Feb 5 | ALMS | Alumis Inc. Common Stock | Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst. | Closed | -1.9% |
| Jan 7 | Jan 14 | ALMS | Alumis Inc. Common Stock | Selected due to recent Phase 3 clinical trial success on 2026-01-07 driving strong near-term momentum and technical breakout; event-driven upside expected from FDA submission and regulatory catalysts. | Closed | +35.8% |